title: Oral administration of prednisone to control refractory vertigo in Ménière's disease: a pilot study.
abstract: OBJECTIVE
  To establish whether the oral administration of moderate doses of prednisone reduces refractory vertigo in Ménière's disease.
  
  
  METHODS
  Blinded, randomized, controlled trial.
  
  
  METHODS
  Tertiary referral center.
  
  
  METHODS
  Patients with Ménière's disease with limited vertigo control (Class C) and severe disability (Scale 3).
  
  
  METHODS
  Two groups (n = 8 per group) were treated orally with either diphenidol (25 mg/d) plus acetazolamide (250 mg/48 h) (control group), or the same treatment plus prednisone (0.35 mg/kg) daily for 18 weeks (prednisone group).
  
  
  METHODS
  The variables evaluated were the frequency and duration of vertigo, tinnitus, aural fullness, and audiographic parameters. The clinical surveillance was performed for 12 months after prednisone withdrawal.
  
  
  RESULTS
  The frequency and duration of vertigo episodes were reduced by 50% and 30%, respectively, by prednisone treatment. Prednisone-treated patients manifested a significant reduction in tinnitus. No changes were observed in aural fullness or hearing. No metabolic or infectious disorders were observed.
  
  
  CONCLUSIONS
  Oral prednisone helps to control refractory vertigo in Ménière's disease. These preliminary data suggest that prednisone can be a good noninvasive antivertigo management regimen for these patients.
authors.affiliation: Department of Otolaryngology, Hospital de Especialidades del Centro Medico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Morales-Luckie
authors.forename: Arnulfo
authors.initials: A
authors.lastname: Cornejo-Suarez
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Zaragoza-Contreras
authors.forename: Oscar
authors.initials: O
authors.lastname: Gonzalez-Perez
mesh_terms: D000284:Administration, Oral; D000328:Adult; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D010865:Pilot Projects; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D014012:Tinnitus / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D014717:Vertigo / Q000209:etiology / Q000517:prevention & control*
chemical_list: D005938:Glucocorticoids; D011241:Prednisone